马拉维罗合成路线图解
Graphical synthetic routes of maraviroc
摘要
马拉维罗（maraviroc,1）化学名为4,4-二氟-N-[（1S）-3-[（1R,5S）-3-（3-甲基-5-异丙基-1,2,4-三唑-4-基）-8-氮杂双环[3.2.1]-8-辛基]-1-苯基丙基]环己烷-1-甲酰胺,是由美国辉瑞公司开发的治疗艾滋病的新药。该药于2007年8月在美国上市，商品名为Selzentry；同年9月又通过了欧盟委员会的审批，在欧洲上市，商品名为Celsentri。马拉维罗可选择性拮抗辅助受体CCR5，阻断HIV-1包膜糖蛋白与CCR5结合从而阻止病毒颗粒侵入和感染宿主细胞。在临床治疗中，马拉维罗能显著降低艾滋病患者体内的病毒载量，在一定程度上降低了艾滋病的致死率^[1-3]。
出处
《中国药物化学杂志》
CAS
CSCD
2012年第2期170-172,共3页
Chinese Journal of Medicinal Chemistry
参考文献10
-
1王珍燕,卢洪洲.抗HIV新药--CCR5拮抗剂马拉韦罗[J].中国艾滋病性病,2008,14(4):431-434. 被引量：3
-
2TUNG R.Preparation of deuterated triazolyl tropane derivatives as CCR5receptor inhibitors[].WO.2008
-
3HAYCOCK-LEWANDOWSKI S J,WILDER A,AHMAN J.Development of a bulk enabling route to maraviroc (UK-427,857),a CCR-5receptor antago-nist[].Organic Process Research and Development.2008
-
4HAYCOCK-LEWANDOWSKI S J,AHMAN J,BIRCH M,et al.Process research and scale-up of a commercialisable route to maraviroc (UK-427,857),a CCR-5receptor antagonist[].Organic Process Research and Development.2008
-
5ZHAO G L,LIN S,KOROTVICKA A,et al.Asym-metric synthesis of maraviroc (UK-427,857)[].Advanced Synthesis and Catalysis.2010
-
6GANT T G,SARSHAR S.8-Azabicyclo[3.2.1]oc-tane-base compounds,preparation and utility of CCR5inhibitors and use in the treatment of infec-tions[].US.2008
-
7PARRA J,PORTILLA J,PULIDO F,et al.Clinical utility of maraviroc[].Clinical Drug Investigation.2011
-
8LOU S,MOQUIST P N,SCHAUS S E.Asymmetric allylboration of acyl imines catalyzed by chiral diols[].Journal of the American Chemical Society.2007
-
9Dorr P,Westby M,Dobbs S,et al.Maraviroc(UK-427,857),a po-tent,orally bioavailable,and selective small-molecule inhibitor of chemokine receptor CCR5with broad-spectrumanti-humanimmunod-eficiency virus type1activity[].Antimicrobial Agents and Chemotherapy.2005
-
10D. A. Price,S. Gayton,M. D. Selby,J. Ahman,S. Haycock-Lewandowski,B. L. Stammen,A. Warren.Initial synthesis of UK-427,857 (Maraviroc)[].Tetrahedron Letters.2005
二级参考文献12
-
1O' Brien SJ, Moore JP.The effect of genetic vaiation in chemokines and their receptors on HIV transmission and progression to AIDS[J].Immunol Rev,2000,177:99 - 111.
-
2Dorr P,Westby M,Dobbs S,et al. Maraviroc(UK-427,857),a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity [ J ] .Antimicrob Agents Chemother, 2005,49( 11 ) : 4721 - 4732.
-
3VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. Criteria for Use : Maraviroc (Selzentry) Available at http://www.pbm. va. gov/criteria/Maraviroc.20 % Criteria 20% for 20% Use20% (Check-Box 20% Format).pdf Accessed on Nov 2,2007.
-
4Briggs DR, Tuttle DL, Sleasman JW, et al. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages) [J]. AIDS, 2000,14 (18) : 2937 - 2939.
-
5Skrabal K, Low AJ, Dong W, et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic mode [J].J Clin Microbiol,2007,45(2) :279 - 284.
-
6MeHale M,Abel S,Russell D,et al.Overview of phase 1 and 2a safety and efficacy data of maraviroc ( UK-427,857 )[A] . Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment [ C]. 2005, Rio de Janeiro, Brazil. Abstract Tuoa 0204.
-
7Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1[J] .Nat Med,2005,11(11) :1170- 1172.
-
8Pfizer Inc. Press Release: Maraviroc Reduces HIV Viral Load IN Treatment-Naive Patients, 48 Week Data Show (press release)[Z]. 2007.
-
9Lalezari J, Goodrich J, DeJesus E. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremia ART-experienced patients infected with CCR5-tropic HIV-1:24-week results of a Phase 2b/3 study in the US and Canada[ Z]. Postrer presented at the 14th Conference on Retroviruses and Opportunistic Infections;2007 February 25 - 28 ; Los Angeles, CA, USA.
-
10Nelson M, Fatkenheuer G, Konourina I. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremia ART-experienced patients infected with CCRS-tropic HIV-1 in Europe,Australia,and North America:24-week results[ Z]. Poster presented at the 14th Conference on Retroviruses and Opportunistic Infections;2007 February 25 - 28 ; Los Angeles, CA, USA.
共引文献2
-
1石英,刘宁,计云霞,魏征,张彤,陈德喜,娄金丽.外周血CD4^+T淋巴细胞表面CCR5受体表达水平与HIV感染关系的研究[J].首都医科大学学报,2010,31(6):711-714. 被引量：1
-
2张霞.高效液相色谱法测定马拉韦罗片的含量[J].中国新药与临床杂志,2012,31(2):110-112.
-
1任业明,赵思太,孔祥雨,张波,刘宪华.抗病毒药物——马拉维若(maraviroc)[J].齐鲁药事,2011,30(4):247-247.
-
2黄胜炎（摘）.国外新批准上市的药物新制剂新剂型（120）[J].中国制药信息,2007,23(12):15-18.
-
3陈兰妹,胡春.Maraviroc(Selzentry)[J].中国药物化学杂志,2008,18(1):79-79.
-
4世界药研之窗[J].中国药科大学学报,2008,39(4):385-388.
-
5美批准-抗艾滋药上市对肝和心脏有副作用[J].医药世界,2007(9):63-63.
-
6Heather Ciliberto,Michael Ciliberto,Andreé Briend,Per Ashorn,Dennis Bier,Mark Manary,胡恩坦.补充抗氧化剂对预防马拉维儿童恶性营养不良的作用:随机、双盲、安慰剂对照试验[J].英国医学杂志中文版,2005,8(4):258-258.
-
7赵越平,杨静,奚苗苗,常瑛,金鑫,丁莉坤,文爱东.LC-MS法测定人血浆中消旋卡多曲活性代谢物的浓度[J].中国药房,2009,20(11):824-826.
-
8袁红.辉瑞公司抗HIV新药Selzentry获FDA批准[J].国外医药（抗生素分册）,2007,28(5):236-236.
-
9郭宗儒.抑制HIV1病毒侵入的首创药物马拉维罗[J].药学学报,2016,51(5):839-842.
-
10袁红.FDA批准辉瑞公司抗HIV新药Maraviroc[J].国外医药（抗生素分册）,2007,28(5):235-235.
